Skip to content

Released May 14, 2026, after the close

10-Q filed May 14, 2026, 44 days after period end · 0001213900-26-056651

Q1 2026 · 10-Q
Revenue—
Net Income$4.34MN/M vs Q1 2025+0.2% vs Q4 2025
EPS, diluted—
Operating Income-$132,030N/M
Operating Cash Flow-$102,503N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2026Q1 2025
Net Income$4.34M-$59.33K

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR